Voyager Therapeutics (NASDAQ: VYGR) shares Q3 2025 results update

Rhea-AI Filing Summary

Voyager Therapeutics, Inc. filed a Form 8-K to report that it announced its third quarter 2025 financial results and corporate updates. The company did this by issuing a press release dated November 10, 2025, which is included with the filing as Exhibit 99.1 under Item 2.02.

The press release is treated as “furnished” rather than “filed,” meaning it is not automatically subject to certain Exchange Act liabilities and will only be incorporated into other securities filings if specifically referenced. The filing also identifies Voyager’s common stock, traded on the Nasdaq Global Select Market under the symbol VYGR, and is signed by Alfred Sandrock, M.D., Ph.D., the company’s Chief Executive Officer, President, and Director.

0001640266false00016402662025-11-102025-11-10

​

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

​

FORM 8-K

​

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of The Securities Exchange Act of 1934

​

Date of Report (Date of Earliest Event Reported): November 10, 2025

Voyager Therapeutics, Inc.

(Exact name of registrant as specified in its charter)

​

​	​	​	​	​
Delaware	​	001-37625	​	46-3003182
(State or other jurisdiction of incorporation)	​	(Commission File Number)	​	(I.R.S. Employer Identification No.)

​

​	​	​
75 Hayden Avenue Lexington, Massachusetts	​	02421
(Address of principal executive offices)	​	(Zip Code)

​

Registrant’s telephone number, including area code (857) 259-5340

​

​

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

​

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

​

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, $0.001 par value	VYGR	Nasdaq Global Select Market

​

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

​

​

​

Item 2.02. Results of Operations and Financial Condition.

On November 10, 2025, Voyager Therapeutics, Inc. (the “Company”) announced third quarter 2025 financial results and corporate updates. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference herein.

​

The information in Item 2.02 of this Current Report on Form 8-K (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

​

Item 9.01. Financial Statements and Exhibits

(d)    Exhibits

​

The following exhibit relating to Item 2.02 shall be deemed to be furnished, and not filed:

​

​	​	​
Exhibit No.	​	Description
​	​	​
99.1	​	Press release dated November 10, 2025 entitled “Voyager Reports Third Quarter 2025 Financial and Operating Results”.
104	​	Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).
​	​	​

​

​

2

SIGNATURES

​

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

​

​

ar	​	​
Date: November 10, 2025	VOYAGER THERAPEUTICS, INC.
​	​
​	By:	/s/ Alfred Sandrock, M.D., Ph.D.
​	​	Alfred Sandrock, M.D., Ph.D.
​	​	Chief Executive Officer, President, and Director (Principal Executive Officer)

​

​

​

​

​

​

​

​

3

FAQ

What did Voyager Therapeutics (VYGR) disclose in this Form 8-K?

Voyager Therapeutics, Inc. disclosed that it announced its third quarter 2025 financial results and corporate updates. The details of those results are contained in a press release dated November 10, 2025, which is furnished as Exhibit 99.1.

Which period’s results are covered in Voyager Therapeutics’ latest update?

The update covers Voyager Therapeutics, Inc.’s financial results and corporate updates for the third quarter of 2025, as stated in the description of the November 10, 2025 press release.

How is the Voyager Therapeutics Q3 2025 press release treated for SEC purposes?

The Q3 2025 press release furnished as Exhibit 99.1 is treated as “furnished” under Item 2.02 of the Form 8-K, not “filed,” and therefore is not automatically subject to Section 18 liabilities or incorporated by reference into other filings unless expressly referenced.

What exhibits are included with this Voyager Therapeutics (VYGR) Form 8-K?

The Form 8-K includes Exhibit 99.1, a press release dated November 10, 2025 titled “Voyager Reports Third Quarter 2025 Financial and Operating Results,” and Exhibit 104, the cover page interactive data file formatted as Inline XBRL.

On which exchange is Voyager Therapeutics’ common stock listed and under what symbol?

Voyager Therapeutics, Inc.’s common stock, with a par value of $0.001 per share, is listed on the Nasdaq Global Select Market under the trading symbol VYGR.

Who signed the Voyager Therapeutics Form 8-K for the Q3 2025 results announcement?

The Form 8-K was signed on behalf of Voyager Therapeutics, Inc. by Alfred Sandrock, M.D., Ph.D., who is identified as Chief Executive Officer, President, and Director, serving as the principal executive officer.